BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Ben Graham Buys in Pharma: Gilead (GILD) and Teva (TEVA)]]>http://www.bloggingstocks.com/2010/10/14/gilead-and-teva-ben-graham-buys-in-pharma/http://www.bloggingstocks.com/2010/10/14/gilead-and-teva-ben-graham-buys-in-pharma/http://www.bloggingstocks.com/2010/10/14/gilead-and-teva-ben-graham-buys-in-pharma/#commentsTeva logo"Among our latest buy recommendations -- based on the value investing strategy of Ben Graham -- we like Gilead Sciences (GILD) and Teva Pharmaceutical (TEVA)," says J. Royden Ward.

The editor of Cabot Benjamin Graham Value Letter explains, "Gilead is a biopharmaceutical company that discovers, develops and markets therapeutic treatments to combat viral, bacterial and fungal infections. Its shares undervalued at 9.7 times forward 12-month EPS.

"Teva, based in Israel, develops, makes and sells generic and proprietary-branded (store brand) drugs. Its shares are clearly undervalued at 10.6 times forward EPS. We consider both stocks to be very low risk.

Continue reading Ben Graham Buys in Pharma: Gilead (GILD) and Teva (TEVA)

Ben Graham Buys in Pharma: Gilead (GILD) and Teva (TEVA) originally appeared on BloggingStocks on Thu, 14 Oct 2010 11:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>ben grahamcabot benjamin graham value letterdrug stocksfeaturedgeneric drug stocksGILDGilead Sciencesj. royden wardpharma stockspharmaceutical stockssteven halperntevaTeva Pharmaceuticalsthestockadvisors.comvalue investingvalue stocksThu, 14 Oct 2010 11:00:00 EST<![CDATA[Closing Bell: A Wishy-Washy Trading Day (AAPL, YHOO, GILD, CYBS, V, VITC, GS)]]>http://www.bloggingstocks.com/2010/04/21/closing-bell-wishy-washy-trading-aapl-yhoo-gild-cybs-v-vi/http://www.bloggingstocks.com/2010/04/21/closing-bell-wishy-washy-trading-aapl-yhoo-gild-cybs-v-vi/http://www.bloggingstocks.com/2010/04/21/closing-bell-wishy-washy-trading-aapl-yhoo-gild-cybs-v-vi/#commentsWith yet another day of little economic news, strong Apple earnings could not drive the market in any single direction throughout the trading day. International news took a backseat to US earnings reports and to intra-day headlines. Whether these markets were going to close in the red or black was not clear until today's final minutes of trading.

Here were the unofficial closing bell levels:

Dow 11,124.85 +7.79 (0.07%)
S&P 500 1,205.88 -1.29 (-0.11%)
Nasdaq 2,504.61 +4.30 (0.17%)

Top Analyst Calls

Continue reading Closing Bell: A Wishy-Washy Trading Day (AAPL, YHOO, GILD, CYBS, V, VITC, GS)

Closing Bell: A Wishy-Washy Trading Day (AAPL, YHOO, GILD, CYBS, V, VITC, GS) originally appeared on BloggingStocks on Wed, 21 Apr 2010 16:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>cybersourcegilead scienceslloyd blankfeinLloydBlankfeinvitacostWed, 21 Apr 2010 16:00:00 EST<![CDATA[Gilead (GILD) shelves blood pressure drug]]>http://www.bloggingstocks.com/2009/12/15/gilead-gild-shelves-blood-pressure-drug/http://www.bloggingstocks.com/2009/12/15/gilead-gild-shelves-blood-pressure-drug/http://www.bloggingstocks.com/2009/12/15/gilead-gild-shelves-blood-pressure-drug/#commentsFiled under: , , , ,

GILD logoGilead Sciences (GILD - option chain) stock is trading lower today after the company announced last night that its hypertension treatment darusentan missed the primary goal of a Phase III trial. As a result, GILD says it has ended development of the drug in favor of spending resources on other products in its pipeline. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on GILD.

This morning, GILD opened at $45.90. So far today the stock has hit a high of $46.28 and a low of $45.01. As of 12:15, GILD is trading at $45.18, down $1.78 (-3.8%). The chart for GILD looks bullish and S&P gives GILD a positive 5 STARS (out of 5) strong buy ranking.

Continue reading Gilead (GILD) shelves blood pressure drug

Gilead (GILD) shelves blood pressure drug originally appeared on BloggingStocks on Tue, 15 Dec 2009 13:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>drug trialsDrugTrialsGILDGilead SciencesGileadScienceshypertensioninthenewsInvestors ObserverInvestorsObserveroptionsTue, 15 Dec 2009 13:20:00 EST<![CDATA[Gilead (GILD): New potential in 4-in-1 HIV drug]]>http://www.bloggingstocks.com/2009/11/05/gilead-gild-new-potential-in-4-in-1-hiv-drug/http://www.bloggingstocks.com/2009/11/05/gilead-gild-new-potential-in-4-in-1-hiv-drug/http://www.bloggingstocks.com/2009/11/05/gilead-gild-new-potential-in-4-in-1-hiv-drug/#commentsFiled under: , ,

"Gilead Sciences (NASDAQ: GILD) develops treatments for life-threatening diseases and specializes in drugs for HIV, the virus that causes AIDS," notes Hannah Choe.

The contributing editor to Personal Finance explains, "Already the market leader in HIV antivirals, Gilead is in the beginning stages of developing Quad, the first-ever, four-in-one AIDS pill.

"The manufacture of HIV drugs, which accounts for more than three-quarters of revenue, is Gilead's highest-grossing business. This segment has held up through the recession; in the second quarter product sales for the antiviral franchise grew 26% from a year ago to $1.41 billion.

Continue reading Gilead (GILD): New potential in 4-in-1 HIV drug

Gilead (GILD): New potential in 4-in-1 HIV drug originally appeared on BloggingStocks on Thu, 05 Nov 2009 13:10:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>aids drug stocksbiotech stocksbiotechnology stocksdrug development stocksgildgilead scienceshannah choehiv drug stockspersonal financequad 4-in-1 aids drugsteven halpernStevenHalpernthestockadvisors.comThu, 05 Nov 2009 13:10:00 EST<![CDATA[The week in preview: High hopes for Apple, Chipotle, Travelers and more]]>http://www.bloggingstocks.com/2009/10/18/the-week-in-preview-high-hopes-for-apple-chipotle-travelers-a/http://www.bloggingstocks.com/2009/10/18/the-week-in-preview-high-hopes-for-apple-chipotle-travelers-a/http://www.bloggingstocks.com/2009/10/18/the-week-in-preview-high-hopes-for-apple-chipotle-travelers-a/#commentsFiled under: , , , , ,

Last week, Goldman Sachs Group Inc. (NYSE: GS) and JPMorgan Chase & Co. (NYSE: JPM) reported stellar quarterly results. Lots more third quarter reports from the big banks are due this week.

However, analysts surveyed by Thomson Reuters anticipate year-over-year earnings declines from Bank of New York Mellon (NYSE: BK), BB&T Corp. (NYSE: BBT), M&T Bank Corp. (NYSE: MTB), Northern Trust Corp. (NASDAQ: NTRS), PNC Financial Services Group Inc. (NYSE: PNC), State Street Corp. (NYSE: STT), US Bancorp (NYSE: USB), and Wells Fargo & Co. (NYSE: WFC).

Continue reading The week in preview: High hopes for Apple, Chipotle, Travelers and more

The week in preview: High hopes for Apple, Chipotle, Travelers and more originally appeared on BloggingStocks on Sun, 18 Oct 2009 12:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>AAPLAppleCBChipotleChubbCMGearnngsfeaturedGILDGilead SciencesGoldman SachsGSJPMJPMorganMicrosoftMSFTTravelersTRVSun, 18 Oct 2009 12:30:00 EST<![CDATA[Turnaround expert targets laggard pharmaceuticals]]>http://www.bloggingstocks.com/2009/10/12/turnaround-expert-targets-laggard-pharmaceuticals/http://www.bloggingstocks.com/2009/10/12/turnaround-expert-targets-laggard-pharmaceuticals/http://www.bloggingstocks.com/2009/10/12/turnaround-expert-targets-laggard-pharmaceuticals/#commentsFiled under: , , , , ,

"Being contrarians, we are always looking for laggard stocks with the potential to rebound," says turnaround expert George Putnam.

In his The Turnaround Letter, the advisor reviews four medical and pharmaceutical stocks that have been among the worst performers in the S&P 100 since the market bottom. Despite their poor performance, he thinks they may be due for a rebound.

"We think that investors who got left behind by the first leg of the market rally are struggling to catch up.

Continue reading Turnaround expert targets laggard pharmaceuticals

Turnaround expert targets laggard pharmaceuticals originally appeared on BloggingStocks on Mon, 12 Oct 2009 12:10:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>abbott labsAbbottLabsabtbaxbaxter internationalBaxterInternationalbmybristol myers squibbBristolMyersSquibbdrug developmentdrug stocksDrugDevelopmentDrugStocksgeorge putnamgildgilead scienceshealthcare stocksmedical stocksMedicalStockssteven halpernStevenHalpernthestockadvisors.comturnaround letterTurnaroundLetterMon, 12 Oct 2009 12:10:00 EST<![CDATA[Gilead (GILD): 'A stock for all seasons']]>http://www.bloggingstocks.com/2009/09/25/gilead-gild-a-stock-for-all-seasons/http://www.bloggingstocks.com/2009/09/25/gilead-gild-a-stock-for-all-seasons/http://www.bloggingstocks.com/2009/09/25/gilead-gild-a-stock-for-all-seasons/#commentsFiled under: , ,

"Gilead Sciences (NASDAQ: GILD), one of the world's largest biotechs, is a stock for all seasons," say growth expert Alexander Green.

The investment director for The Oxford Club explains, "It's a fine company with a solid balance sheet, a recession-proof business and excellent growth prospects."

"Gilead focuses on three main areas, including cardiovascular conditions and respiratory diseases. (Many may have taken its anti-influenza drug Tamiflu, Letairis to treat hypertension, or Macugen to treat macular degeneration.)

Continue reading Gilead (GILD): 'A stock for all seasons'

Gilead (GILD): 'A stock for all seasons' originally appeared on BloggingStocks on Fri, 25 Sep 2009 13:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>alex greenalexander greenbiotech stocksbiotechnology stocksdrug development stocksgildgilead scienceshealthcarehealthcare stockshiv drug stocksoxford clubthestockadvisors.comFri, 25 Sep 2009 13:00:00 EST<![CDATA[The week in preview: Earnings crunch expected to reveal lots of lower profits]]>http://www.bloggingstocks.com/2009/07/19/the-week-in-preview-earnings-crunch-expected-to-reveal-lots-of/http://www.bloggingstocks.com/2009/07/19/the-week-in-preview-earnings-crunch-expected-to-reveal-lots-of/http://www.bloggingstocks.com/2009/07/19/the-week-in-preview-earnings-crunch-expected-to-reveal-lots-of/#commentsFiled under: , ,

The earnings crunch begins in earnest this week, and analysts surveyed by Thomson Reuters are expecting a parade of companies reporting profit declines in the just completed quarter. That includes more financials, such as American Express Co. (NYSE: AXP), Bank of New York Mellon Corp. (NYSE: BK), M&T Bank Corp. (NYSE: MTB), Northern Trust Corp. (NASDAQ: NTRS), State Street Corp. (NYSE: STT), US Bancorp (NYSE: USB), and Wells Fargo & Co. (NYSE: WFC). On the other hand, Capital One Financial Corp. (NYSE: COF), E*Trade Financial Corp. (NASDAQ: ETFC), Regions Financial Corp. (NYSE: RF), and Zions Bancorp. (NASDAQ: ZION) are expected to post losses.

This week's anticipated earnings decliners also include tech companies such as Apple Inc. (NASDAQ: AAPL), Lexmark International Inc. (NYSE: LXK), Microsoft Corp. (NASDAQ: MSFT), Qualcomm Inc. (NASDAQ: QCOM), Texas Instruments Inc. (NYSE: TXN), and Yahoo! Inc. (NASDAQ: YHOO). Advanced Micro Devices Inc. (NYSE: AMD) is expected to post a loss.

Continue reading The week in preview: Earnings crunch expected to reveal lots of lower profits

The week in preview: Earnings crunch expected to reveal lots of lower profits originally appeared on BloggingStocks on Sun, 19 Jul 2009 13:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>AAIAirtranDGXearningsGILDGilead SciencesQuest DiagnosticsRaytheonRTNTractor SupplyTSCOSun, 19 Jul 2009 13:00:00 EST<![CDATA[Gilead Sciences enters drug agreement with Tibotec Pharmaceuticals]]>http://www.bloggingstocks.com/2009/07/17/gilead-sciences-enters-drug-agreement-with-tibotec-pharmaceutica/http://www.bloggingstocks.com/2009/07/17/gilead-sciences-enters-drug-agreement-with-tibotec-pharmaceutica/http://www.bloggingstocks.com/2009/07/17/gilead-sciences-enters-drug-agreement-with-tibotec-pharmaceutica/#commentsFiled under:

Yesterday, Gilead Sciences (NASDAQ: GILD) announced that it entered a license and collaboration agreement with Tibotec Pharmaceuticals. The two firms will combine to develop and commercialize a new once-daily, fixed-dose treatment for HIV. GILD's CEO John Martin noted, "Gilead and Tibotec share a strong focus on bringing safe and effective treatment options to people living with HIV/AIDS."

If the collaboration is approved, GILD will assume the lead in manufacturing, registration, distribution, and commercialization of a fixed-dose combination of Truvada and rilpivirine. GILD will not be responsible for the commercialization of this combination in the developing world and Japan, which will be handled by Tibotec. The two companies will work toward an agreement to market the combination in the developing world.

Continue reading Gilead Sciences enters drug agreement with Tibotec Pharmaceuticals

Gilead Sciences enters drug agreement with Tibotec Pharmaceuticals originally appeared on BloggingStocks on Fri, 17 Jul 2009 12:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>AIDSAIDS treatmentAidsTreatmentgildgilead sciencesGileadSciencesHIVinthenewspharmaceuticalsTibotecFri, 17 Jul 2009 12:20:00 EST<![CDATA[Biotech stock #1: Gilead Sciences (GILD)]]>http://www.bloggingstocks.com/2009/07/11/biotech-stock-1-gilead-sciences-gild/http://www.bloggingstocks.com/2009/07/11/biotech-stock-1-gilead-sciences-gild/http://www.bloggingstocks.com/2009/07/11/biotech-stock-1-gilead-sciences-gild/#commentsFiled under: ,

biotech stocks gileadFew would argue with the claim that Gilead Sciences (NASDAQ: GILD) is the best-managed biopharma company on the planet.

It dominates the HIV treatment market and gets a 19%-plus royalty on Tamiflu, which is used to treat H1N1 (swine) flue. Gilead also has several drugs on or headed for the market to treat pulmonary disease and hard-to-treat high blood pressure.

Your best strategy for life-changing profits?

Buy the stock and sell the calls (then use the cash to buy puts on the market, which is headed down further.) Or buy long-term calls and keep an eye on them.

Next: Biotech Stock #2

Biotech stock #1: Gilead Sciences (GILD) originally appeared on BloggingStocks on Sat, 11 Jul 2009 09:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>gildgilead sciencesGileadSciencesmichael shulmanMichaelShulmanstocks to buyStocksToBuytop stocksTopStocksSat, 11 Jul 2009 09:00:00 EST<![CDATA[Six bang-for-your-buck biotech stocks]]>http://www.bloggingstocks.com/2009/07/11/6-bang-for-your-buck-biotech-stocks/http://www.bloggingstocks.com/2009/07/11/6-bang-for-your-buck-biotech-stocks/http://www.bloggingstocks.com/2009/07/11/6-bang-for-your-buck-biotech-stocks/#commentsFiled under: ,

biotech stocksLast year, as the market sank, one group actually went up -- large-cap, cashflow positive biotech and genomics companies.

This year, interest has shifted to the little guys -- the speculative biotech stocks that could be 10- or 20-baggers with one breakthrough.

Here are six biotech stocks with the potential to deliver life-changing profits:

Biotech Stock #1: Gilead Sciences (NASDAQ: GILD)
Biotech Stock #2: Questcor Pharmaceuticals (NASDAQ: QCOR)

Biotech Stock #3: Cepheid (NASDAQ: CPHD)
Biotech Stock #4: Curis (NASDAQ: CRIS)
Biotech Stock #5: Cerus Corp. (NASDAQ: CERS)
Biotech Stock #6: Illumina (NASDAQ: ILMN)

Six bang-for-your-buck biotech stocks originally appeared on BloggingStocks on Sat, 11 Jul 2009 08:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biotech stocksBiotechStockscepheidcerus corpCerusCorpcurisfeaturedgilead sciencesGileadSciencesilluminamichael shulmanMichaelShulmanquestcor pharmaceuticalsQuestcorPharmaceuticalsstocks to buyStocksToBuytop stocksTopStocksSat, 11 Jul 2009 08:00:00 EST<![CDATA[Analyst upgrades, downgrades and initiations: TGT, SWY, CSIQ, HOTT, MPEL, RIO, CPB, CVD and HGG]]>http://www.bloggingstocks.com/2009/05/21/analyst-upgrades-downgrades-and-initiations-tgt-swy-csiq-ho/http://www.bloggingstocks.com/2009/05/21/analyst-upgrades-downgrades-and-initiations-tgt-swy-csiq-ho/http://www.bloggingstocks.com/2009/05/21/analyst-upgrades-downgrades-and-initiations-tgt-swy-csiq-ho/#commentsFiled under: , , , , , , , , ,

Analyst upgrades:
  • UBS upgraded Target (NYSE: TGT) to Buy from Neutral and raised its price target to $52 from $45 citing reduced inventories, some credit stability, and an improved back-to-school period.
  • Credit Suisse said concerns regarding Safeway's (NYSE: SWY) price position are overblown and that earnings risk is limited. The firm upgraded shares to Outperform from Neutral and raised the target price to $25 from $22.
  • Oppenheimer upgraded Canadian Solar (NASDAQ: CSIQ) to Outperform from Perform as it believes the story is underappreciated following the recent sector rally. The firm has a $14 price target on the stock.
  • CME Group (NASDAQ: CME) was upgraded to buy from Neutral at Goldman.
  • Freeport McMoRan (NYSE: FCX) was upgraded to Overweight from Neutral at JP Morgan.
  • Gilead Sciences (NASDAQ: GILD) was upgraded to Buy from Neutral at FTN Equity.

Continue reading Analyst upgrades, downgrades and initiations: TGT, SWY, CSIQ, HOTT, MPEL, RIO, CPB, CVD and HGG

Analyst upgrades, downgrades and initiations: TGT, SWY, CSIQ, HOTT, MPEL, RIO, CPB, CVD and HGG originally appeared on BloggingStocks on Thu, 21 May 2009 11:10:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Campbell SoupCampbellSoupCanadian SolarCanadianSolarCICignaCMECME GroupCmeGroupCovanceCPBCSIQCVDFCXfreeport mcmoranFreeportMcmoranGILDGilead SciencesGileadSciencesHGGhhgreggHot TopicHOTTHotTopicMelcoMelco CrownMelcoCrownMPELMT BankMTBMtBankPerrigoPETMPetSmartPRGORIOSafewaySTPsuntechsuntech powerSuntechPowerSWYtargettarget corp.TargetCorp.TellabsTGTTLABValeThu, 21 May 2009 11:10:00 EST<![CDATA[Analyst upgrades, downgrades and initiations: LEN, RDC, FFIN, SII, AN, ACHN, UA, LULU, JST]]>http://www.bloggingstocks.com/2009/05/18/analyst-upgrades-downgrades-and-initiations-len-rdc-ffin-si/http://www.bloggingstocks.com/2009/05/18/analyst-upgrades-downgrades-and-initiations-len-rdc-ffin-si/http://www.bloggingstocks.com/2009/05/18/analyst-upgrades-downgrades-and-initiations-len-rdc-ffin-si/#commentsFiled under: , , , , , , , ,

Analyst upgrades:
  • Citigroup upgraded Lennar (NYSE: LEN) to Buy from Hold as it believes the company's near-term liquidity profile is improved following the $400M debt issuance. The firm raised its target price to $12 from $11.
  • Jefferies upgraded Rowan Companies (NYSE: RDC) to Buy from Hold as it believes jack-up drillers will continue to outperform deepwater names. The firm raised its target price to $27 from $20.
  • Keefe Bruyette upgraded First Financial (NASDAQ: FFIN) to Market Perform from Underperform to reflect more positive loan data for the Texas banks. The firm raised its target price on shares to $44 from $38.
  • MGM Mirage (NYSE: MGM) was upgraded to Overweight from Neutral at JP Morgan.
  • Morgan Stanley (NYSE: MS) was upgraded to Outperform from Market Perform at JMP Securities.
  • Brinker (NYSE: EAT) was upgraded to Overweight from Equal Weight at Barclays.

Continue reading Analyst upgrades, downgrades and initiations: LEN, RDC, FFIN, SII, AN, ACHN, UA, LULU, JST

Analyst upgrades, downgrades and initiations: LEN, RDC, FFIN, SII, AN, ACHN, UA, LULU, JST originally appeared on BloggingStocks on Mon, 18 May 2009 10:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>AchillionACHNAllegheny EnergyAlleghenyEnergyAMCCANAnglogoldApplied MicroAppliedMicroAUAutoNationAYEBrinkerbrinker internationalBrinkerInternationalDean FoodsDeanFoodsDFEATFFINFirst FinancialFirstFinancialGILDgileadgilead sciencesGileadSciencesj. crewJ.CrewJCGJinpan InternationalJinpanInternationalJSTLENLennarMGMMGM MirageMgmMirageMorgan StanleyMorganStanleyMSRDCRowan CompaniesRowanCompaniesSIISmith InternationalSmithInternationalUAUnder ArmourUnderArmourMon, 18 May 2009 10:30:00 EST<![CDATA[Analyst upgrades, downgrades and initiations: DNDN, ANDE, the auto sector, DGX, MTB, ADVS, ITG, MF and PCLN ]]>http://www.bloggingstocks.com/2009/04/22/analyst-upgrades-downgrades-and-initiations-dndn-ande-the-au/http://www.bloggingstocks.com/2009/04/22/analyst-upgrades-downgrades-and-initiations-dndn-ande-the-au/http://www.bloggingstocks.com/2009/04/22/analyst-upgrades-downgrades-and-initiations-dndn-ande-the-au/#commentsFiled under: , , , , , , , , , , , ,

Analyst upgrades:
  • Merriman upgraded Dendreon (NASDAQ: DNDN) to Buy from Neutral on expectations shares will react positively to the full IMPACT data release on April 28. The firm thinks Provenge could represent the first cancer immunotherapy approved in the U.S. and raised its valuation range on the stock to $33-$34 from $18-$19.
  • Piper Jaffray upgraded Andersons (NASDAQ: ANDE) as it believes the valuation is attractive, investor expectations are low, and the company's fertilizer and rail segments could recovery in FY10. The firm has a $19 target on shares. Goldman upgraded the auto sector to Neutral from Cautious and added Ford (NYSE: F) to its Conviction Buy list. The analyst does not believe Ford will have to declare bankruptcy and sees the company benefiting from Chrysler share declines and GM's (NYSE: GM) reduced product offerings. Ford's price target is $6
  • Banc of America/Merrill upgraded U.S. Airways (NYSE: LCC) to Buy from Underperform.
  • Broadcom (NASDAQ: BRCM) was upgraded to Equal Weight from Underweight at Morgan Stanley.
  • Caterpillar (NYSE: CAT) was raised to Overweight from Neutral at JP Morgan.

Continue reading Analyst upgrades, downgrades and initiations: DNDN, ANDE, the auto sector, DGX, MTB, ADVS, ITG, MF and PCLN

Analyst upgrades, downgrades and initiations: DNDN, ANDE, the auto sector, DGX, MTB, ADVS, ITG, MF and PCLN originally appeared on BloggingStocks on Wed, 22 Apr 2009 13:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Advent SoftwareAdventSoftwareADVSANDEAndersonsauto sectorAutoSectorBRCMBroadcomCATCaterpillarChryslerCLcolgatecolgate-palmoliveDean FoodsDeanFoodsDendreonDGXDNDNDTDuetsche TelekomDuetscheTelekomFFordGeneral MotorsGeneralMotorsGILDGilead SciencesGileadSciencesGMInvestment Technology GroupInvestmentTechnologyGroupITGKnight capitalKnightCapitalLCCLMTLockheed MartinLockheedMartinMFMF GlobalMfGlobalMT BankMTBMtBankNITEPCLNPricelinePriceline.comProvengeQuest DiagnosticsQuestDiagnosticsRHHBYRocheU.S. AirwaysU.s.AirwaysWed, 22 Apr 2009 13:20:00 EST<![CDATA[The week in preview: Eye on financial, tech, health care earnings]]>http://www.bloggingstocks.com/2009/04/19/the-week-in-preview-eye-on-financial-tech-health-care-earning/http://www.bloggingstocks.com/2009/04/19/the-week-in-preview-eye-on-financial-tech-health-care-earning/http://www.bloggingstocks.com/2009/04/19/the-week-in-preview-eye-on-financial-tech-health-care-earning/#commentsFiled under: , , ,

The earnings crunch is on. Among the many companies scheduled to report quarterly results this week are such so-called bellwether stocks as Amazon.com Inc. (NASDAQ: AMZN), Caterpillar Inc. (NYSE: CAT), Coca-Cola Co. (NYSE: KO), DuPont (NYSE: DD), and United Parcel Service Inc. (NYSE: UPS), all of which analysts surveyed by Thomson Reuters expect to report lower earnings for the recent quarter. Altria Group Inc. (NYSE: MO), McDonald's Corp. (NYSE: MCD), and Raytheon Co. (NYSE: RTN), on the other hand, are expected to post marginal earnings growth.

Continue reading The week in preview: Eye on financial, tech, health care earnings

The week in preview: Eye on financial, tech, health care earnings originally appeared on BloggingStocks on Sun, 19 Apr 2009 12:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>ALGTAllegiant TravelAxsysAXYSbellwhether stocksCNXCONSOL Energyearningsfinancial stocksGILDGilead Scienceshealth care stocksRBCAARepublic Bancorptech stocksSun, 19 Apr 2009 12:30:00 EST<![CDATA[Gilead (GILD) gets positive blood pressure drug trial results]]>http://www.bloggingstocks.com/2009/04/03/gilead-gild-gets-positive-blood-pressure-drug-trial-results/http://www.bloggingstocks.com/2009/04/03/gilead-gild-gets-positive-blood-pressure-drug-trial-results/http://www.bloggingstocks.com/2009/04/03/gilead-gild-gets-positive-blood-pressure-drug-trial-results/#commentsFiled under: , , , ,

GILD logoGilead Sciences (NASDAQ: GILD - option chain) shares are headed higher today after the company reported positive results from a blood pressure drug trial. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on GILD.

GILD opened this morning at $48.31. So far today the stock has hit a low of $46.03 and a high of $48.37. As of 11:35, GILD is trading at $46.49, up $1.79 (4.0%). The chart for GILD looks bullish and S&P gives GILD a positive 4 STARS (out of 5) buy ranking.

Continue reading Gilead (GILD) gets positive blood pressure drug trial results

Gilead (GILD) gets positive blood pressure drug trial results originally appeared on BloggingStocks on Fri, 03 Apr 2009 13:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>drug trialDrugTrialGILDGilead SciencesGileadSciencesinthenewsInvestors ObserverInvestorsObserveroptionsFri, 03 Apr 2009 13:30:00 EST<![CDATA[Gilead Sciences (GILD) Q4 earnings & '09 outlook impress]]>http://www.bloggingstocks.com/2009/01/28/gilead-sciences-gild-q4-earnings-and-09-outlook-impress/http://www.bloggingstocks.com/2009/01/28/gilead-sciences-gild-q4-earnings-and-09-outlook-impress/http://www.bloggingstocks.com/2009/01/28/gilead-sciences-gild-q4-earnings-and-09-outlook-impress/#commentsFiled under: , , , , , ,

GILD logoGilead Sciences (NASDAQ: GILD - option chain) shares are headed higher today after the company posted a fourth-quarter profit of $568.2 million, or 60 cents per share, on revenue of $1.43 billion. Excluding one-time items, GILD earned $598.5 million, or 63 per share, beating analysts' projections of 55 cents per share. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on GILD.

GILD opened this morning at $49.42. So far today the stock has hit a low of $49.20 and a high of $51.15. As of 12:25, GILD is trading at $51.03, up $2.80 (5.8%). The chart for GILD looks bullish and S&P gives GILD a positive 4 STARS (out of 5) buy ranking.

Continue reading Gilead Sciences (GILD) Q4 earnings & '09 outlook impress

Gilead Sciences (GILD) Q4 earnings & '09 outlook impress originally appeared on BloggingStocks on Wed, 28 Jan 2009 13:06:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>earningsforecastGILDGilead SciencesGileadSciencesInvestors ObserverInvestorsObserveroptionsWed, 28 Jan 2009 13:06:00 EST<![CDATA[Options Update: Biopharmaceuticals' volatility flat into EPS]]>http://www.bloggingstocks.com/2009/01/27/options-update-biopharmaceuticals-volatility-flat-into-eps/http://www.bloggingstocks.com/2009/01/27/options-update-biopharmaceuticals-volatility-flat-into-eps/http://www.bloggingstocks.com/2009/01/27/options-update-biopharmaceuticals-volatility-flat-into-eps/#commentsFiled under: ,

Celgene (NASDAQ: CELG), a biopharmaceutical company, closed at $50.34. CELG is scheduled to announce Q4 EPS on January 29. CELG February and March option implied volatility of 49 is near its 26-week average according to Track Data, suggesting non-directional price movement.

Genzyme (NASDAQ: GENZ) closed at $68.20. GENZ is expected to report Q4 EPS on February 11. Robert W Baird has an $87 price target on GENZ. GENZ February option implied volatility of 40 is near its 26-week average according to Track Data, suggesting non-directional price movement.

Gilead Sciences (NASDAQ: GILD), a biopharmaceutical company, is scheduled to report Q4 EPS on January 27. GILD February option implied volatility of 46 is near its 26-week average according to Track Data, suggesting non-directional price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Options Update: Biopharmaceuticals' volatility flat into EPS originally appeared on BloggingStocks on Tue, 27 Jan 2009 08:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biopharmaceutical companyBiopharmaceuticalCompanycelgCelgenegenzGenzymegildGilead SciencesGileadSciencesTue, 27 Jan 2009 08:00:00 EST<![CDATA[Gilead (GILD): 'Best life sciences firm on the planet']]>http://www.bloggingstocks.com/2008/10/20/gilead-gild-best-life-sciences-firm-on-the-planet/http://www.bloggingstocks.com/2008/10/20/gilead-gild-best-life-sciences-firm-on-the-planet/http://www.bloggingstocks.com/2008/10/20/gilead-gild-best-life-sciences-firm-on-the-planet/#commentsFiled under: , ,

"Long-term, Gilead Sciences (NASDAQ: GILD) is the best life sciences company on the planet," says biotechnology specialist Michael Shulman in The ChangeWave Biotech Investor.

"Auto sales may plunge, home sales may stay in the tank and retail sales may fall, but disease, old age and human frailty are undeniably 'forever.'

"While the economy in 2009 is almost certainly going to contract, analysts expect the sale of biologic drugs and other life sciences products to increase 12%-15% -- with some winners growing much faster.

"The winners will be rewarded, even in a bear market. In the past year, Gilead has outperformed the Nasdaq by more than 30 percentage points -- and it's doing it as a mature biotech.

Continue reading Gilead (GILD): 'Best life sciences firm on the planet'

Gilead (GILD): 'Best life sciences firm on the planet' originally appeared on BloggingStocks on Mon, 20 Oct 2008 15:40:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biotech stocksbiotechnologyBiotechStockschangewave biotech investorChangewaveBiotechInvestordrug developmentDrugDevelopmentgildgilead sciencesGileadScienceshiv treatmentHivTreatmentlife sciencesmichael shulmanMichaelShulmanrecession-resistant stocksRecession-resistantStockssteven halpernStevenHalpernthestockadvisors.comMon, 20 Oct 2008 15:40:00 EST<![CDATA[Gilead Sciences (GILD) reports higher Q1 profit but outlook disappoints]]>http://www.bloggingstocks.com/2008/04/17/gilead-sciences-gild-reports-higher-q1-profit-but-outlook-disa/http://www.bloggingstocks.com/2008/04/17/gilead-sciences-gild-reports-higher-q1-profit-but-outlook-disa/http://www.bloggingstocks.com/2008/04/17/gilead-sciences-gild-reports-higher-q1-profit-but-outlook-disa/#commentsFiled under: , , ,

Shares of biotechnology company Gilead Sciences Inc. (NASDAQ: GILD) have been plunging this morning, despite the firm posting better-than-expected first quarter earnings per share. Hurting the stock this morning is the company's full-year sales guidance, which was unchanged.

Gilead Sciences reported late yesterday that its profit during the first-quarter jumped 22% to $496.1 million, or 51 cents per share, boosted by strong HIV treatments Atripla and Truvada sales. These numbers are up from $407.4 million, or 43 cents per share reported in the same period a year ago. Analysts' forecast was for lower earnings of 47 cents per share in the quarter.

The company's quarterly revenue also surged by a respectable 22% to $1.26 billion. For this period, the company benefited from strong gains from combination HIV treatment Atripla which came with sales of $342.2 million, a 70 percent rise. HIV drugs sales also saw a growth of 37% to $964.7 million. Analysts, on average, expected Gilead Sciences's sales to be $1.22 billion, according to Reuters Estimates.

Continue reading Gilead Sciences (GILD) reports higher Q1 profit but outlook disappoints

Gilead Sciences (GILD) reports higher Q1 profit but outlook disappoints originally appeared on BloggingStocks on Thu, 17 Apr 2008 12:25:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biotechnologydrugearningsfeaturedforecastgildGilead SciencesGileadSciencesinthenewsThu, 17 Apr 2008 12:25:00 EST